Sökning: onr:"swepub:oai:DiVA.org:uu-351265" > Neoadjuvant Therapy...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05910naa a2200553 4500 | |
001 | oai:DiVA.org:uu-351265 | |
003 | SwePub | |
008 | 180611s2018 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:137735442 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3512652 URI |
024 | 7 | a https://doi.org/10.1016/j.clcc.2017.09.0022 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1377354422 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Babaei, Masoudu German Canc Res Ctr, Div Clin Epidemiol & Aging Res, INF 581, Heidelberg, Germany.4 aut |
245 | 1 0 | a Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II to III Across European Countries :b Variations and Outcomes |
264 | 1 | b Elsevier BV,c 2018 |
338 | a print2 rdacarrier | |
520 | a This study is the largest observational study on neoadjuvant therapy in patients with stage II & III rectal cancer by including high-quality data from large population-based and clinical cancer registries. We observed large variations in administration of neoadjuvant chemo(radio) therapy across European countries. Our results support major survival advantages of patients treated with neoadjuvant radiotherapy. Background: Neoadjuvant therapy improves survival of patients with clinical stage II and III rectal cancer in clinical trials. In this study, we investigated the administration of neoadjuvant radiotherapy (neo-RT) and neoadjuvant chemoradiotherapy (neo-CRT) and its association with survival in resected patients in 2 European countries (The Netherlands and Sweden) and at 3 specialist centers. Materials and Methods: Administration of neoadjuvant treatment (all registries) and overall survival after surgery in The Netherlands and Sweden were assessed. Hazard ratios (HRs) were obtained using Cox regression adjusted for potential confounders. Results: A total of 16,095 rectal cancer patients with clinical stage II and III were eligible for analyses. Large variations in administration of neo-RT and neo-CRT were observed. Elderly patients less often received neo-RT and neo-CRT. Patients with stage III disease received neo-CRT more frequently than neo-RT. Administration of neo-RT versus surgery without neoadjuvant treatment was significantly associated with improved survival in The Netherlands (HR, 0.62; 95% confidence interval [CI], 0.53-0.73) as well as in Sweden (HR, 0.79; 95% CI, 0.69-0.90). Administration of neo-CRT was associated with enhanced survival in The Netherlands (HR, 0.62; 95% CI, 0.50-0.78) but not in Sweden (HR, 0.97; 95% CI, 0.80-1.18). The mortality of patients treated with neo-CRT compared with neo-RT showed inconsistent results in population-based centers. Conclusions: Our results support an association of neo-RT with enhanced survival among stage II and III rectal cancer patients. Comparing neo-CRT with neo-RT, larger variations and inconsistent results with respect to survival were observed across centers. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a Long-term outcomes | |
653 | a Neoadjuvant therapy | |
653 | a Rectal cancer | |
653 | a Survival | |
653 | a Variations | |
700 | 1 | a Jansen, Linau German Canc Res Ctr, Div Clin Epidemiol & Aging Res, INF 581, Heidelberg, Germany.4 aut |
700 | 1 | a Balavarca, Yesildau German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany.;Natl Ctr Tumor Dis, Heidelberg, Germany.4 aut |
700 | 1 | a Sjovall, Annikau Karolinska Institutet4 aut |
700 | 1 | a Bos, Amandau Comprehens Canc Org Netherlands, Utrecht, Netherlands.;Erasmus MC Univ Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands.4 aut |
700 | 1 | a van de Velde, Tonyu Netherlands Canc Inst, Biometr Dept, Amsterdam, Netherlands.4 aut |
700 | 1 | a Moreau, Michelu Inst Jules Bordet, Datactr, Brussels, Belgium.4 aut |
700 | 1 | a Liberale, Gabrielu Inst Jules Bordet, Datactr, Brussels, Belgium.4 aut |
700 | 1 | a Goncalves, Ana Filipau Portuguese Oncol Inst Porto, Porto, Portugal.4 aut |
700 | 1 | a Bento, Maria Joseu Portuguese Oncol Inst Porto, Porto, Portugal.4 aut |
700 | 1 | a Ulrich, Cornelia M.u German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany.;Natl Ctr Tumor Dis, Heidelberg, Germany.;German Canc Res Ctr, German Canc Consortium, Heidelberg, Germany.4 aut |
700 | 1 | a Schrotz-King, Petrau German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany.;Natl Ctr Tumor Dis, Heidelberg, Germany.4 aut |
700 | 1 | a Lemmens, Valeryu Comprehens Canc Org Netherlands, Utrecht, Netherlands.;Erasmus MC Univ Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands.4 aut |
700 | 1 | a Glimelius, Bengtu Uppsala universitet,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)bengglim |
700 | 1 | a Brenner, Hermannu German Canc Res Ctr, Div Clin Epidemiol & Aging Res, INF 581, Heidelberg, Germany.;German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany.;Natl Ctr Tumor Dis, Heidelberg, Germany.;German Canc Res Ctr, German Canc Consortium, Heidelberg, Germany.4 aut |
710 | 2 | a German Canc Res Ctr, Div Clin Epidemiol & Aging Res, INF 581, Heidelberg, Germany.b German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany.;Natl Ctr Tumor Dis, Heidelberg, Germany.4 org |
773 | 0 | t Clinical colorectal cancerd : Elsevier BVg 17:1, s. E129-E142q 17:1<E129-E142x 1533-0028x 1938-0674 |
856 | 4 | u https://europepmc.org/articles/pmc6002839?pdf=render |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-351265 |
856 | 4 8 | u https://doi.org/10.1016/j.clcc.2017.09.002 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:137735442 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.